MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q3
hinzugefügt 14.11.2022
Tricida Anteile 2011-2026 | TCDA
Anteile Jährlich Tricida
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 51.3 M | 50 M | 47.5 M | 22.1 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 51.3 M | 22.1 M | 42.7 M |
Anteile Vierteljährlich Tricida
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 58 M | 57.8 M | 57.7 M | 55.4 M | 50.4 M | 50.3 M | 50.2 M | 50.2 M | 50.1 M | 50 M | 49.8 M | 49.8 M | 49.4 M | 48.7 M | 42.3 M | 42.1 M | 41.3 M | 2.33 M | 2.28 M | 2.27 M | 2.24 M | 2.15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 58 M | 2.15 M | 39.3 M |
Anteile anderer Aktien in der Arzneimittelhersteller
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
46.3 M | - | - | $ 754 M |  USA |
 |
Alimera Sciences
ALIM
|
25.6 M | - | - | $ 142 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
25.8 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
150 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
2.16 M | - | 10.11 % | $ 58.2 M | USA |
 |
Canopy Growth Corporation
CGC
|
108 M | $ 1.04 | -3.7 % | $ 112 M |  Canada |
 |
Cronos Group
CRON
|
350 M | $ 2.59 | -1.34 % | $ 1.34 B | Canada |
 |
Catalent
CTLT
|
181 M | - | - | $ 11.5 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
95.1 M | - | - | $ 2.06 B |  France |
 |
Evolus
EOLS
|
64.5 M | $ 5.84 | 4.38 % | $ 376 M | USA |
 |
China Pharma Holdings
CPHI
|
17.5 M | $ 0.6 | 3.05 % | $ 10.5 M |  China |
 |
DURECT Corporation
DRRX
|
26.3 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
14.1 M | $ 3.53 | -3.81 % | $ 49.6 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
12.9 M | - | -39.89 % | $ 27.7 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
50.8 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Endo International plc
ENDP
|
235 M | - | - | $ 28.9 M |  Irlanda |
 |
HEXO Corp.
HEXO
|
127 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
3.34 M | - | - | $ 36.6 M | USA |
 |
Harrow Health
HROW
|
36.8 M | $ 36.45 | -7.06 % | $ 1.34 B | USA |
 |
Aurora Cannabis
ACB
|
169 M | $ 3.5 | -4.11 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
6.54 M | - | -23.39 % | $ 1.76 M | USA |
 |
Jupiter Wellness
JUPW
|
54.4 M | - | - | $ 33.6 M | USA |
 |
Emergent BioSolutions
EBS
|
51.2 M | $ 8.44 | -3.76 % | $ 432 M | USA |
 |
Assertio Holdings
ASRT
|
71 M | $ 11.93 | -1.16 % | $ 847 M | USA |
 |
Bausch Health Companies
BHC
|
365 M | $ 5.55 | -1.42 % | $ 2.03 B | Canada |
 |
Lannett Company
LCI
|
40.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
132 M | $ 2.88 | 0.17 % | $ 379 M | USA |
 |
OrganiGram Holdings
OGI
|
256 M | $ 1.45 | 4.32 % | $ 402 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
492 K | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
138 M | $ 11.35 | -2.91 % | $ 1.57 B | USA |
 |
Sundial Growers
SNDL
|
1.86 M | $ 1.53 | -0.97 % | $ 3.37 M | Canada |
 |
TherapeuticsMD
TXMD
|
10.4 M | $ 2.27 | 5.02 % | $ 23.7 M | USA |
 |
ProPhase Labs
PRPH
|
15.8 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
135 M | $ 2.51 | -0.2 % | $ 339 M | USA |
 |
Viatris
VTRS
|
1.2 B | $ 14.47 | -1.67 % | $ 17.4 B | USA |
 |
Radius Health
RDUS
|
47.2 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
4.31 M | $ 0.71 | -8.05 % | $ 3.06 M | USA |
 |
Rockwell Medical
RMTI
|
23.3 M | $ 0.88 | -1.32 % | $ 20.5 M | USA |
 |
Pacira BioSciences
PCRX
|
46.2 M | $ 22.83 | -0.13 % | $ 1.06 B | USA |
 |
PetIQ
PETQ
|
29.1 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
112 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
23.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
95.2 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
30.1 M | $ 4.43 | -7.13 % | $ 133 M | USA |
 |
SCYNEXIS
SCYX
|
49.9 M | $ 0.78 | 0.65 % | $ 38.9 M | USA |
 |
Solid Biosciences
SLDB
|
40.8 M | $ 5.59 | -8.93 % | $ 228 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
1.24 M | $ 2.53 | -9.82 % | $ 3.14 M | USA |
 |
Tilray
TLRY
|
618 M | $ 7.02 | -3.84 % | $ 4.34 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
42.7 M | - | - | $ 55.5 M | USA |